EUCTR2004-002172-42-AT进行中（未招募）不适用
A randomized, double-blind, double-dummy, multicenter, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediately after nerve-sparing prostatectomy for improving erectile function. - REINVENT (Recovery of Erection: Intervention with Vardenafil Early Nightly Therapy
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 828
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •At Screening:
- •Males 18-64 years of age
- •Scheduled to undergo bilateral nerve-sparing radical retropubic BNSRRP, as selected according to the investigator’s usual clinical practice
- •Surgery scheduled within about 1 month of screening (Visit 1)
- •Expressed an interest in resuming sexual activity as soon as possible after prostatectomy
- •Heterosexual relationship.
- •No pre-operative erectile dysfunction: International Index of Erectile Function (IIEF) Erectile Function Domain Score score EF domain =26 at screening (Visit 1) without any therapy/devices for improvement of erections. No previous use of any therapy/devices for erectile dysfunction
- •Historical total prostate specific antigen (PSA) <10 ng/mL
- •Gleason Tumor Score = 7 on biopsy
- •No perforation of the prostate capsule by tumor: Clinical stage pre-operatively T1c to T2a/2b
- •Documented, signed and dated written Informed Consent
- •At Randomization:
- •Bilateral nerve-sparing during the retropubic prostatectomy documented on the operating report
- •BNSRRP occurred within approximately 1 month post screening (Visit 1)
- •No perforation of the prostate capsule by tumor: No positive tumor margins confirmed after surgery: =T2 stage on pathology report from the surgery
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •At Screening:
- •A)Previous or Current Medical Conditions:
- •Any unstable medical, psychiatric, or substance abuse disorder that, in the opinion of the investigator, is likely to affect the subject's ability to complete the study or precludes the subject’s participation in the study
- •Presence of penile anatomical abnormalities (e.g. penile fibrosis or Peyronie’s disease) in the opinion of the Investigator would significantly impair sexual performance
- •Primary hypoactive sexual desire
- •Spinal cord injury
- •Hereditary degenerative retinal disorders such as retinitis pigmentosa
- •History of positive test for Hepatitis B surface antigen (HbsAg) or Hepatitis C
- •Severe chronic or acute liver disease, including history of moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment
- •Clinically significant chronic hematological disease which may lead to priapism such as sickle cell anemia, multiple myeloma or leukemia
- •Bleeding disorder
- •Significant active peptic ulceration
- •Any underlying cardiovascular condition including unstable angina pectoris that would preclude sexual activity
- •History of myocardial infarction, stroke, or life-threatening arrhythmia within the prior 6 months
- •Uncontrolled atrial fibrillation/flutter at screening (ventricular response rate > 100 bpm)
- •Resting hypotension (a resting systolic blood pressure of <90 mm Hg) or hypertension (a resting systolic blood pressure >170 mm Hg or a resting diastolic blood pressure >110 mm Hg)
- •Symptomatic postural hypotension within 6 months of Visit 1
- •History of malignancy within the past 5 years (other than prostate cancer or squamous or basal cell skin cancer)
- •Life expectancy <3 years
- •Clinical diagnosis of significant untreated sleep apnea or working night shifts (e.g. 23:00h to 7:00 h).
- •Diabetes mellitus: type I, type II with presence of end organ symptomatology (e.g. peripheral neuropathy, nephropathy, retinopathy, amyotrophy)
- •B) Concomitant Medication:
- •Nitrates or nitric oxide donors
- •Oral or injectable androgens
- •Anti-androgens
- •Any of the following potent inhibitors of cytochrome P- 450 3A4: HIV protease inhibitors such as ritonavir or indinavir; anti-mycotic agents itraconazole and ketoconazole (topical forms are allowed); or erythromycin
- •Any investigational drug (including placebo) within 30 days of Visit 1
- •Any treatment for ED historically or during the study, including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories
- •Alpha blockers
- •C) Abnormal Laboratory Values:
- •Serum total testosterone level >25% below the lower limit of normal (according to the range of the testing laboratory).
- •Serum creatinine > 3.0 mg/dL.
- •Elevation of AST and/or ALT >3X the ULN
- •D) Other Exclusions:
- •Known hypersensitivity to vardenafil, Bay 38-9456 (also known as SB-782528) or any component of the investigational medication
- •Illiterate or are unable to understand the questionnaires or subject diary
- •Unwilling or unable to complete the subject diary or questionnaires
- •At Randomization:
- •Residual prostate cancer, or requirement for radiotherapy or ADT
- •Need for a re-exploration surgery due to hemorrhage
- •Need for urethral catheter expected to be =3 weeks due to anastomotic fistula
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind, double-dummy, multicenter, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediately after nerve-sparing prostatectomy for improving erectile function - REINVENT (Recovery of Erection: Intervention with Vardenafil Early Nightly Therapy)MedDRA version: 8.1Level: LLTClassification code 10061461Term: Erectile dysfunctionErectile DysfunctionEUCTR2004-002172-42-GBBayer Healthcare AG
进行中（未招募）
不适用
A randomized, double-blind, double-dummy, multicenter, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediately after nerve-sparing prostatectomy for improving erectile functioErectile DysfunctionEUCTR2004-002172-42-ITBAYER
进行中（未招募）
不适用
A randomized, double-blind, double-dummy, multicenter, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediately after nerve-sparing prostatectomy for improving erectile function - REINVENT (Recovery of Erection: Intervention with Vardenafil Early Nightly Therapy)MedDRA version: 8.1Level: LLTClassification code 10061461Term: Erectile dysfunctionErectile DysfunctionEUCTR2004-002172-42-DEBayer Healthcare AG1,000
进行中（未招募）
不适用
A randomized, double-blind, double-dummy, multicenter, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediately after nerve-sparing prostatectomy for improving erectile function. - REINVENT (Recovery of Erection: Intervention with Vardenafil Early Nightly TherapyErectile DysfunctionEUCTR2004-002172-42-SEBayer Healthcare AG828
进行中（未招募）
1 期
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.CTIS2023-509606-30-00Faes Farma S.A.502